You are here

  • Home
  • Archive
  • Volume 75, Issue Suppl 2
  • THU0439 52-Week Efficacy and Safety of Apremilast and Switch from Etanercept in Patients with Moderate To Severe Psoriasis: Results from The Liberate Study

Citation Tools

Article menu
Download PDFPDF
Poster Presentations
Psoriatic arthritis
THU0439 52-Week Efficacy and Safety of Apremilast and Switch from Etanercept in Patients with Moderate To Severe Psoriasis: Results from The Liberate Study

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Reich K, Soung J, Gooderham M, et al
THU0439 52-Week Efficacy and Safety of Apremilast and Switch from Etanercept in Patients with Moderate To Severe Psoriasis: Results from The Liberate Study
Annals of the Rheumatic Diseases 2016;75:349.